PTCT
PTC Therapeutics, Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth +16.7% ·
share flow +14.1% ·
net new positions +14.3%
· formula
Broad accumulation: rising shares across more holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q1 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 2 | 0 | 18.67K | $1.18M | n/a | −1 |
| Q2 2026 | 113 | +8 | 59.00M | $4.80B | +13 | −7 |
| Q1 2026 | 110 | -8 | 65.31M | $4.45B | +9 | −18 |
| Q4 2025 | 117 | 0 | 67.93M | $5.16B | +1 | n/a |
| Q3 2025 | 22 | +2 | 38.04M | $2.33B | +2 | n/a |
| Q2 2025 | 17 | 0 | 34.63M | $1.69B | +1 | −1 |
| Q1 2025 | 14 | +2 | 16.93M | $862.87M | +2 | n/a |
| Q4 2024 | 12 | 0 | 14.84M | $670.12M | n/a | n/a |
| Q3 2024 | 11 | -2 | 14.00M | $519.42M | n/a | −2 |
| Q2 2024 | 13 | n/a | 14.28M | $436.54M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Wellington Management ✦ | 5.42M | +13.2% | $276.16M | 0.1% | ▲ Add | 4 | SEC ↗ ×8 |
| 2 | State Street Global Advisors ✦ (passive) | 2.45M | -9.3% | $125.10M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 3 | Geode Capital Management ✦ (passive) | 1.87M | +4.3% | $95.51M | 0.0% | ▲ Add | 4 | SEC ↗ ×2 |
| 4 | D. E. Shaw & Co. ✦ | 1.45M | -6.3% | $73.65M | 0.1% | ▼ Trim | 4 | SEC ↗ ×3 |
| 5 | Point72 Asset Management ✦ | 1.37M | -4.8% | $70.00M | 0.2% | ▼ Trim | 4 | SEC ↗ |
| 6 | Citadel Advisors ✦ | 1.17M | +154.9% | $59.50M | 0.1% | ▲ Add | 4 | SEC ↗ |
| 7 | Marshall Wace ✦ | 741.00K | New | $37.76M | 0.1% | New | 1 | SEC ↗ |
| 8 | Renaissance Technologies ✦ | 670.20K | +2.6% | $34.15M | 0.1% | ▲ Add | 4 | SEC ↗ |
| 9 | Adage Capital Partners ✦ | 595.00K | +94.0% | $30.32M | 0.1% | ▲ Add | 4 | SEC ↗ |
| 10 | T. Rowe Price ✦ | 468.55K | -8.0% | $23.88M | 0.0% | ▼ Trim | 4 | SEC ↗ ×2 |
| 11 | AQR Capital Management ✦ | 413.02K | +162.5% | $21.05M | 0.0% | ▲ Add | 4 | SEC ↗ ×5 |
| 12 | Millennium Management ✦ | 224.84K | -27.3% | $11.46M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 13 | Two Sigma Investments ✦ | 80.10K | -53.8% | $4.08M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 14 | Gotham Asset Management ✦ | 4.80K | New | $244,608 | 0.0% | New | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| Marshall Wace | $37.76M | 0.1% |
| Gotham Asset Management | $244,608 | 0.0% |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 348 holders, 95.15M shares, $6.33B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Director · 382 sh · $22,973
Director · 2.12K sh · $126,063
Officer · 192 sh · $12,338
Director · 2.45K sh · $155,091
Director · 53 sh · $3,389
Officer · 435 sh · $27,910
Officer · 1.64K sh · $104,881
Director · 376 sh · $25,737
Director · 9.62K sh · $652,796
Director · 7.01K sh · $471,854
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology